Abstract: The present invention provides microfluidic technology enabling rapid and economical manipulation of reactions on the femtoliter to microliter scale.

Abstract: The present invention relates to peptides and protein mimetics and their therapeutic and research use. In particular, the present invention provides synthetic, stabilized DNA binding domain peptides and methods of using such peptides as therapeutic agents.

Abstract: Provided are a semiconductor device including a two-dimensional material and a method of manufacturing the semiconductor device. The semiconductor device may include a substrate, first and second two-dimensional material layers on the substrate and junctioned to each other in a lateral direction to form a coherent interface, a first source electrode and a first drain electrode on the first two-dimensional material layer, a first gate electrode between the first source electrode and the first drain electrode, a second source electrode and a second drain electrode on the second two-dimensional material layer, and a second gate electrode between the second source electrode and the second drain electrode.

Abstract: Cavity resonators are promising resources for quantum technology, while native nonlinear interactions for cavities are typically too weak to provide the level of quan-turn control required to deliver complex targeted operations. Here we investigate a scheme to engineer a target Hamiltonian for photonic cavities using ancilla qubits. By off-resonantly driving dispersively coupled ancilla qubits, we develop an optimized approach to engineering an arbitrary photon-number dependent (PND) Hamiltonian for the cavities while minimizing the operation errors. The engineered Hamiltonian admits various applications including canceling unwanted cavity self-Kerr interac-tions, creating higher-order nonlinearities for quantum simulations, and designing quantum gates resilient to noise. Our scheme can be implemented with coupled microwave cavities and transmon qubits in superconducting circuit systems.

Abstract: Optofluidic devices configured confine liquid crystals within a fluidic channel under the application of acoustic waves and pressure-driven flow and related methods of use are described.

Abstract: In aspects, the present disclosure provides a method of treating or preventing uterine fibroids (UF) or polycystic ovary syndrome (PCOS) in a female mammal, the method comprising, consisting essentially of, or consisting of administering to the female mammal an effective amount of doxercalciferol. In aspects, the present disclosure provides a method of treating insulin resistance, infertility, obesity, and/or hyperandrogenism related to PCOS in a female mammal.

Abstract: Provided herein are anti-neuraminidase agents useful for neutralization of influenza virus infection, and methods of use and manufacture thereof. In particular, compositions comprising anti-neuraminidase agents (e.g., antibodies) that are cross-reactive with multiple influenza strains are provided, as well as methods of treatment and prevention of influenza infection therewith.

Abstract: Provided herein are anti-neuraminidase agents useful for neutralization of influenza virus infection, and methods of use and manufacture thereof. In particular, compositions comprising anti-neuraminidase agents (e.g., antibodies) that are cross-reactive with multiple influenza strains are provided, as well as methods of treatment and prevention of influenza infection therewith.

Abstract: Embodiments are directed to kits and methods of treating a breast cancer patient with a glucocorticoid receptor antagonist with or without an anticancer agent or compound after the patient has been determined to be susceptible to treatment with the glucocorticoid receptor antagonist.

Abstract: Nanoparticles comprising micheliolide (MCL) or derivatives thereof, and optionally additional therapeutic agents, such as chemotherapeutic agents, are described. Also described are methods of treating diseases, such as cancer, comprising the use of combinations of MCL or a derivative thereof with X-ray irradiation and/or other therapeutic agents, such as immune checkpoint inhibitors. The use of the combinations can provide synergistic anticancer therapeutic efficacy, for example, as the MCL or derivative thereof can both sensitize cancer cells to therapy and target resistant cancer stem cells (CSCs) for selective cell death.

Abstract: Embodiments are directed to a series of novel small molecule activators of NRF2 dependent gene expression that are evaluated in an effort to develop therapeutic methods against diseases with deregulated KEAP1-NRF2 signaling.

Abstract: Lewis acidic metal-organic framework (MOF) materials comprising triflate-coordinated metal nodes are described. The materials can be used as heterogenous catalysts in a wide range of organic group transformations, including Diels-Alder reactions, epoxide-ring opening reactions, Friedel-Crafts acylation reactions and alkene hydroalkoxylation reactions. The MOFs can also be prepared with metallated organic bridging ligands to provide heterogenous catalysts for tandem reactions and/or prepared as composites with support particles for use in columns of continuous flow reactor systems. Methods of preparing and using the MOF materials and their composites are also described.

Abstract: Provided are freeze-dried (FD) products of biological materials that have improved stability and reduced risk of collapse. The FD products include nanoparticles that are added to formulations including the biological materials prior to freeze-drying. Also described herein are methods of freeze-drying (FD).

Abstract: The disclosure relates to the engineering of collagen-binding modification of masked therapeutic agents comprising one or more tumor-associated protease cleavage sites. Upon exposure to tumor-associated proteases in the tumor microenvironment, the polypeptide is cleaved, which unmasks the therapeutic agent, reducing off-target side effects and toxicity associated with systemic administration. Accordingly, aspects of the disclosure relate to a polypeptide comprising a therapeutic agent linked to a masking agent through a linker, wherein the linker comprises one or more tumor-associated protease cleavage sites, and wherein the masking agent blocks the association of the therapeutic agent to its therapeutic target, and further wherein the polypeptide is operatively linked to a collagen binding domain or a tumor-targeting agent.

Abstract: Disclosed herein are inventive methods of making thin films, inventive thin films, and inventive articles and systems comprising thin films. Certain embodiments are related to methods of making thin films in which reagents are arranged within a first phase and a second phase such that at least one reagent reacts to form a thin film proximate to the interface between the first phase and the second phase. Thin films (including two-dimensional materials) disclosed herein can have one or more of a variety of beneficial properties including large lateral dimension(s), lateral continuity, high mechanical strength, consistent spatial composition, and/or consistent thickness. In accordance with certain embodiments, thin films disclosed herein can be combined to form a variety of inventive multi-layer articles, including multi-layer articles comprising a combination of thin films having different compositions that interact with each other via van der Waals forces.

Abstract: Provided are a superlattice structure including a two-dimensional material and a device including the superlattice structure. The superlattice structure may include at least two different two-dimensional (2D) materials bonded to each other in a lateral direction, and an interfacial region of the at least two 2D materials may be strained. The superlattice structure may have a bandgap adjusted by the interfacial region that is strained. The at least two 2D materials may include first and second 2D materials. The first 2D material may have a first bandgap in an intrinsic state thereof. The second 2D material may have a second bandgap in an intrinsic state thereof. An interfacial region of the first and second 2D materials and an adjacent region may have a third bandgap between the first bandgap and the second bandgap.

Abstract: In aspects, the present disclosure provides methods for quantifying microorganisms. In aspects, the present disclosure provides methods for identifying microorganisms. In aspects, the present disclosure provides methods of analyzing food. In aspects, the present disclosure provides methods of treating a human subject having an infection. In aspects, the present disclosure provides methods of analyzing environmental samples.

Abstract: The methods, compositions, and kits of the disclosure provide a novel approach for a whole genome, unbiased DNA analysis method that can be performed on limited amounts of DNA can be used to analyze DNA to determine its modification status. Aspects of the disclosure relate to a method for amplifying bisulfite-treated deoxyribonucleic acid (DNA) molecules comprising: (a) ligating an adaptor to the DNA molecules, wherein the adaptor comprises a RNA polymerase promoter comprising bisulfite-protected cytosines; (b) treating the ligated DNA molecules with bisulfite; (c) hybridizing the bisulfite-treated DNA molecules with a primer; (d) extending the hybridized primer to make double stranded DNA; and (e) in vitro transcribing the double-stranded DNA to make RNA.

Abstract: Provided herein are compositions comprising Sel1-derived peptides thereof, and method of use thereof for the treatment/prevention excess oxalate levels and conditions and diseases related thereto. In particular, peptides comprise Sel-like repeat (SLR) domains and/or tetratricopeptide (TPR) domains and may be linked together or with other peptides or polypeptides to treat/prevent diseases/conditions related to excess oxalate levels, such as hyperoxaluria and/or hyperoxalemia.

Abstract: Aspects of the present disclosure are directed to NT5E (CD73)-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such NT5E-targeting polypeptides and cells comprising such nucleic acids. Described are methods for treatment of cancer using NT5E-targeting polypeptides.